CN117695387A - 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 - Google Patents
用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 Download PDFInfo
- Publication number
- CN117695387A CN117695387A CN202311544173.5A CN202311544173A CN117695387A CN 117695387 A CN117695387 A CN 117695387A CN 202311544173 A CN202311544173 A CN 202311544173A CN 117695387 A CN117695387 A CN 117695387A
- Authority
- CN
- China
- Prior art keywords
- dose
- hu5f9
- doses
- patients
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 title description 103
- 201000011510 cancer Diseases 0.000 title description 63
- 238000001802 infusion Methods 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 19
- 238000001990 intravenous administration Methods 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 95
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 95
- 210000004027 cell Anatomy 0.000 description 87
- 238000012423 maintenance Methods 0.000 description 85
- 210000003743 erythrocyte Anatomy 0.000 description 78
- 230000037452 priming Effects 0.000 description 78
- 239000003795 chemical substances by application Substances 0.000 description 76
- 238000011282 treatment Methods 0.000 description 56
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 52
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 52
- 230000003442 weekly effect Effects 0.000 description 50
- 208000007502 anemia Diseases 0.000 description 42
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 40
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 229920001184 polypeptide Polymers 0.000 description 32
- 230000027455 binding Effects 0.000 description 30
- 230000001965 increasing effect Effects 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- 231100000682 maximum tolerated dose Toxicity 0.000 description 28
- 102000001554 Hemoglobins Human genes 0.000 description 25
- 108010054147 Hemoglobins Proteins 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 239000003999 initiator Substances 0.000 description 23
- 230000001225 therapeutic effect Effects 0.000 description 22
- 239000011230 binding agent Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 206010057249 Phagocytosis Diseases 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 230000008782 phagocytosis Effects 0.000 description 19
- 238000011287 therapeutic dose Methods 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000002459 sustained effect Effects 0.000 description 17
- 230000004520 agglutination Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000002093 peripheral effect Effects 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 208000032839 leukemia Diseases 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 241000282567 Macaca fascicularis Species 0.000 description 11
- 210000001539 phagocyte Anatomy 0.000 description 11
- 206010038796 reticulocytosis Diseases 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- 230000036210 malignancy Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000003204 osmotic effect Effects 0.000 description 9
- 238000011084 recovery Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000001995 reticulocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 201000005787 hematologic cancer Diseases 0.000 description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001447 compensatory effect Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012292 receptor occupancy assay Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000003782 apoptosis assay Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000001934 delay Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000005522 programmed cell death Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 231100001273 GLP toxicology study Toxicity 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 230000010437 erythropoiesis Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000009101 premedication Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000009738 saturating Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000607 toxicokinetics Toxicity 0.000 description 3
- 231100000402 unacceptable toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 206010022822 Intravascular haemolysis Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 2
- 206010041509 Spherocytic anaemia Diseases 0.000 description 2
- 229940126302 TTI-621 Drugs 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003095 anti-phagocytic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000925 erythroid effect Effects 0.000 description 2
- 230000000913 erythropoietic effect Effects 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 241001289435 Astragalus brachycalyx Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108010058590 CD47 Antigen Proteins 0.000 description 1
- 102000006355 CD47 Antigen Human genes 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010063045 Effusion Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010053430 Erythrophagocytosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009582 blood typing Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 231100001021 decreased hematocrit Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 125000003712 glycosamine group Chemical group 0.000 description 1
- 231100001156 grade 3 toxicity Toxicity 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002652 macrocyte Anatomy 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000005885 phagocytic elimination Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323330P | 2016-04-15 | 2016-04-15 | |
| US62/323,330 | 2016-04-15 | ||
| US201662427679P | 2016-11-29 | 2016-11-29 | |
| US62/427,679 | 2016-11-29 | ||
| CN201780029157.9A CN109152837A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
| PCT/US2017/027662 WO2017181033A1 (en) | 2016-04-15 | 2017-04-14 | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780029157.9A Division CN109152837A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117695387A true CN117695387A (zh) | 2024-03-15 |
Family
ID=60042716
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210926503.6A Pending CN115350276A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
| CN202311544173.5A Pending CN117695387A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
| CN201780029157.9A Pending CN109152837A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210926503.6A Pending CN115350276A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780029157.9A Pending CN109152837A (zh) | 2016-04-15 | 2017-04-14 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472878B2 (enExample) |
| EP (3) | EP4349412A3 (enExample) |
| JP (3) | JP7532009B2 (enExample) |
| KR (3) | KR20230035435A (enExample) |
| CN (3) | CN115350276A (enExample) |
| AU (2) | AU2017250809B2 (enExample) |
| CA (1) | CA3019676A1 (enExample) |
| ES (1) | ES2909835T3 (enExample) |
| PL (1) | PL3442578T3 (enExample) |
| PT (1) | PT3442578T (enExample) |
| SI (1) | SI3442578T1 (enExample) |
| WO (1) | WO2017181033A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| GB201804860D0 (en) | 2018-03-27 | 2018-05-09 | Ultrahuman Two Ltd | CD47 Binding agents |
| CN112601544A (zh) * | 2018-07-05 | 2021-04-02 | 三钰生物科技股份有限公司 | 人类抗cd47抗体及其用途 |
| AU2019349651B2 (en) | 2018-09-27 | 2023-12-07 | Celgene Corporation | SIRP alpha binding proteins and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| EP3817773B1 (en) | 2018-11-26 | 2024-07-24 | Forty Seven, Inc. | Humanized antibodies against c-kit |
| JP2022510634A (ja) | 2018-11-28 | 2022-01-27 | フォーティ セブン， インコーポレイテッド | 除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ |
| RS65480B1 (sr) | 2019-09-18 | 2024-05-31 | Lamkap Bio Alpha AG | Bispecifična antitela protiv ceacam5 i cd3 |
| AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| CN115361971A (zh) * | 2020-04-06 | 2022-11-18 | 里兰斯坦福初级大学理事会 | 抗体制剂 |
| WO2022076928A1 (en) * | 2020-10-09 | 2022-04-14 | Sana Biotechnology, Inc. | METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT |
| US12071481B2 (en) | 2020-12-23 | 2024-08-27 | D-10 Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| WO2022148383A1 (en) * | 2021-01-05 | 2022-07-14 | National Institute Of Biological Sciences, Beijing | A bispecific antibody targeting gpc3 and cd47 |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2735144T3 (es) | 2008-01-15 | 2019-12-16 | Univ Leland Stanford Junior | Métodos para manipular fagocitosis mediada por CD47 |
| CN102202643A (zh) * | 2008-02-07 | 2011-09-28 | 安姆根有限公司 | 稳定化的蛋白组合物 |
| JP6166177B2 (ja) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| SMT202000689T1 (it) | 2012-01-17 | 2021-01-05 | Univ Leland Stanford Junior | Reagenti per sirp-alfa ad alta affinita' |
| SG10201700160RA (en) | 2012-02-06 | 2017-03-30 | Inhibrx Lp | Cd47 antibodies and methods of use thereof |
| CN105101997B (zh) | 2013-02-06 | 2018-11-09 | 印希彼有限合伙公司 | 不减少血小板和不减少血红细胞的cd47抗体及其使用方法 |
| ES2728066T3 (es) * | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| CA2904095A1 (en) | 2013-03-27 | 2014-10-02 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| JP6843611B2 (ja) * | 2013-04-29 | 2021-03-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 免疫を強化する抗ｃｄ４７因子の使用 |
| US10172911B2 (en) | 2013-10-01 | 2019-01-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules |
| WO2015105995A2 (en) * | 2014-01-08 | 2015-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| WO2015189698A2 (en) * | 2014-06-08 | 2015-12-17 | Beijing Cosci-Remd Bio Med Tech Company Ltd | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| US11053314B2 (en) * | 2014-10-10 | 2021-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to eliminate cancer stem cells by targeting CD47 |
| CN115361971A (zh) * | 2020-04-06 | 2022-11-18 | 里兰斯坦福初级大学理事会 | 抗体制剂 |
-
2017
- 2017-04-14 PL PL17783254T patent/PL3442578T3/pl unknown
- 2017-04-14 EP EP24159469.6A patent/EP4349412A3/en active Pending
- 2017-04-14 CN CN202210926503.6A patent/CN115350276A/zh active Pending
- 2017-04-14 AU AU2017250809A patent/AU2017250809B2/en active Active
- 2017-04-14 WO PCT/US2017/027662 patent/WO2017181033A1/en not_active Ceased
- 2017-04-14 CN CN202311544173.5A patent/CN117695387A/zh active Pending
- 2017-04-14 CA CA3019676A patent/CA3019676A1/en active Pending
- 2017-04-14 US US16/089,115 patent/US11472878B2/en active Active
- 2017-04-14 EP EP22155479.3A patent/EP4074339A1/en active Pending
- 2017-04-14 KR KR1020237006777A patent/KR20230035435A/ko not_active Ceased
- 2017-04-14 KR KR1020247002294A patent/KR20240016445A/ko active Pending
- 2017-04-14 KR KR1020187032126A patent/KR102505253B1/ko active Active
- 2017-04-14 EP EP17783254.0A patent/EP3442578B1/en active Active
- 2017-04-14 JP JP2018553360A patent/JP7532009B2/ja active Active
- 2017-04-14 CN CN201780029157.9A patent/CN109152837A/zh active Pending
- 2017-04-14 PT PT177832540T patent/PT3442578T/pt unknown
- 2017-04-14 ES ES17783254T patent/ES2909835T3/es active Active
- 2017-04-14 SI SI201731120T patent/SI3442578T1/sl unknown
-
2022
- 2022-09-02 JP JP2022140214A patent/JP7442591B2/ja active Active
- 2022-09-08 US US17/930,621 patent/US11718670B2/en active Active
-
2023
- 2023-06-15 US US18/210,483 patent/US20230406923A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023723A patent/JP2024059764A/ja active Pending
- 2024-05-22 AU AU2024203396A patent/AU2024203396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024203396A1 (en) | 2024-06-06 |
| US20190106491A1 (en) | 2019-04-11 |
| EP3442578B1 (en) | 2022-02-09 |
| ES2909835T3 (es) | 2022-05-10 |
| US11718670B2 (en) | 2023-08-08 |
| JP2019515899A (ja) | 2019-06-13 |
| JP2024059764A (ja) | 2024-05-01 |
| KR20240016445A (ko) | 2024-02-06 |
| EP4074339A1 (en) | 2022-10-19 |
| EP4349412A2 (en) | 2024-04-10 |
| CA3019676A1 (en) | 2017-10-19 |
| JP7532009B2 (ja) | 2024-08-13 |
| PL3442578T3 (pl) | 2022-06-20 |
| EP3442578A4 (en) | 2019-04-10 |
| WO2017181033A1 (en) | 2017-10-19 |
| AU2017250809A1 (en) | 2018-10-25 |
| EP4349412A3 (en) | 2024-06-12 |
| CN115350276A (zh) | 2022-11-18 |
| SI3442578T1 (sl) | 2022-05-31 |
| JP2022172278A (ja) | 2022-11-15 |
| EP3442578A1 (en) | 2019-02-20 |
| AU2017250809B2 (en) | 2024-02-29 |
| PT3442578T (pt) | 2022-05-19 |
| US20230406923A1 (en) | 2023-12-21 |
| KR102505253B1 (ko) | 2023-03-02 |
| US11472878B2 (en) | 2022-10-18 |
| CN109152837A (zh) | 2019-01-04 |
| KR20180134367A (ko) | 2018-12-18 |
| KR20230035435A (ko) | 2023-03-13 |
| US20230068235A1 (en) | 2023-03-02 |
| JP7442591B2 (ja) | 2024-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442591B2 (ja) | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 | |
| US20240218077A1 (en) | Anti-cd47 agent-based treatment of cd20-positive cancer | |
| JP7308191B2 (ja) | 抗ｃｄ４７剤ベースの卵巣癌療法 | |
| JP6840127B2 (ja) | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 | |
| CN119546335A (zh) | 治疗淋巴瘤的方法 | |
| HK40082292A (en) | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer | |
| HK40080891A (en) | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer | |
| HK40107887A (en) | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer | |
| WO2023185720A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| WO2023198089A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| HK40029258A (en) | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies | |
| HK40029255A (en) | Anti-cd47 agent-based ovarian cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40108467 Country of ref document: HK |